ThyroSeq Announces New Data On Utilization Of ThyroSeq v3 Genomic Classifier At AACE 2018 Meeting
BOSTON, May 15, 2018 /PRNewswire/ -- ThyroSeq® announced today that it will present performance data on utilization of ThyroSeq v3 Genomic Classifier at the upcoming American Association of Clinical Endocrinologists (AACE) 27th Annual Scientific & Clinical Congress. ThyroSeq v3 Genomic Classifier is based on a robust genomic analysis of 112 genes for >12,000 DNA variants, >120 gene fusions, copy number alterations and gene expression alterations. ThyroSeq has more than 10 years of experience with testing indeterminate cytology nodules for molecular markers and over 5 years of utilizing next-generation sequencing. It relies on a proprietary database containing outcomes on thousands of patients with specific genetic alterations to uniquely provide interpretation of the test results, including cancer probability and aggressiveness. This information is essential to assist physicians with offering the most appropriate management for patients with thyroid nodules that have indeterminate cytology. The new "real world" data from more than 20 institutions on 3,783 FNA samples with indeterminate cytology will be presented at the AACE Annual Congress, which is being held May 16-20 in Boston.
"In this large consecutive series of indeterminate cytology nodules tested by ThyroSeq v3 GC, 62% of cases yielded a negative test result, so that diagnostic surgery may be avoided in most of these patients. Among test-positive nodules, ThyroSeq provided more precise assessment of cancer likelihood and potential for recurrence, allowing physicians to offer more individualized patient management," said Yuri Nikiforov, MD, PhD, one of the authors of the study.
The following abstract will provide information on the utility of ThyroSeq for diagnosis and management of patients with indeterminate cytology nodules in multiple clinical centers in the United States:
| Title: |
Real World Experience with ThyroSeq v3 Genomic Classifier in Thyroid Nodules with Indeterminate Cytology: Results of Testing of the First 3,783 Consecutive Samples (Poster #1221) |
| Presenter: |
Yuri E. Nikiforov, M.D., University of Pittsburgh Medical Center |
| Date/Time: |
Saturday, May 19, 10:00 -11:00 a.m. Eastern Time |
| Location: |
Hynes Convention Center, Exhibit Hall |
| ThyroSeq will also host the following reception and presentation event supported by Sonic Healthcare USA: |
|
| Title: |
Applying Genomic Science to Thyroid FNA Diagnosis |
| Presenters: |
Yuri E. Nikiforov, M.D., PhD, University of Pittsburgh Medical Center |
| Steven Hodak, MD, NYU School of Medicine |
|
| Date/Time: |
Thursday, May 17, 7:15-9:15 p.m. Eastern Time |
| Location: |
Top of the Hub, 800 Boylston Street, Boston, MA |
About ThyroSeq
ThyroSeq is an innovative proprietary test, which through 10 years of continuous refinement incorporates all major scientific discoveries and utilizes advanced technology to provide the most accurate diagnosis of whether malignant disease is present in thyroid nodules. For more information, visit www.ThyroSeq.com.
MEDIA CONTACT
Jeanine Wilson
(917)841-8565
[email protected]
SOURCE ThyroSeq
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article